Tenax Therapeutics Faces Securities Class Action Lawsuit
Rosen Law Firm has filed a class action lawsuit against Tenax Therapeutics, alleging the company misled investors regarding the efficacy of its drug candidate, TNX-103.
Investors have initiated a class action lawsuit against Tenax Therapeutics, Inc. concerning trading activities between November 13, 2023, and August 7, 2026. The lawsuit, brought by Rosen Law Firm, claims the company issued materially misleading statements to shareholders.
The complaint alleges that Tenax Therapeutics overstated the clinical, regulatory, and commercial potential of TNX-103. According to the filing, investors suffered financial damages after the alleged discrepancies regarding the drug’s effectiveness were revealed to the market.
The deadline for investors to apply to serve as lead plaintiff in the ongoing litigation is December 28, 2026. Participation in the lawsuit is optional, and class members are not represented until a class is formally certified by the court.